Enzolytics, Inc. (OTC Pink: ENZC) represents one of the most polarizing and complex stories in the microcap biotechnology sector. For years, retail investors have debated whether enzc stock is an undervalued biotech pioneer on the verge of medical breakthroughs or a cautionary tale of corporate mismanagement and regulatory failure. Trading at a sub-penny level of approximately $0.0005 with a market capitalization of under $2 million, the company sits in a high-stakes limbo. On one hand, its proprietary platforms—headlined by the immune therapeutic vaccine ITV-1 and its artificial intelligence-driven monoclonal antibody research—possess speculative scientific merit. On the other hand, a devastating civil fraud lawsuit by the Securities and Exchange Commission (SEC), severe share dilution, ongoing patent disputes, and a drastic 500-to-1 reverse split proposal have cast a long, dark shadow over the company's future. In this comprehensive, up-to-date analysis, we dive deep into the fundamental science, legal battlegrounds, financial realities, and strategic shifts defining enzc stock in 2026.

The Core Science: ITV-1, IPF, and the Enzolytics Biotech Portfolio

To understand the speculative appeal of enzc stock, investors must first examine the biological science that serves as the company's foundation. Enzolytics' research and development pipeline is bifurcated into two primary, complementary methodologies aimed at treating major infectious diseases, auto-immune disorders, and various forms of cancer.

The first pillar is its proprietary Inactivated Pepsin Fragment (IPF) technology, which forms the basis of its flagship therapeutic candidate, ITV-1 (Immune Therapeutic Vaccine-1). Invented by Harry Zhabilov, ITV-1 is a suspension of irreversible inactivated pepsin fraction derived from porcine pepsin. In clinical trials conducted under European Union guidelines at the National Centre of Infectious and Parasitic Diseases in Bulgaria, ITV-1 demonstrated significant immunomodulatory properties. Rather than acting as a standard antiviral drug that directly attacks a pathogen, IPF functions as a biological response modifier. In clinical observations, it was shown to strengthen the host immune system by improving critical immune markers, including absolute counts and percentages of CD3, CD4, and CD8 T-cells, as well as natural killer (NK) cells. For HIV-1 patients, the administration of ITV-1 resulted in a noticeable decrease in viral load and a beneficial impact on opportunistic infections, all while exhibiting excellent compatibility and zero cross-resistance with modern antiretroviral therapies.

The second pillar of Enzolytics' science is its monoclonal antibody (mAb) platform, which was significantly expanded following the company's 2020 merger with BioClonetics Immunotherapeutics, Inc. Under this platform, the company developed "Clone 3," a fully human monoclonal antibody of the IgG1 subclass. Unlike conventional antibodies that target highly mutable regions of the viral envelope—which quickly leads to drug resistance—Clone 3 is engineered to target a highly conserved, immutable site on the gp41 transmembrane glycoprotein of the HIV-1 virus. To advance this technology, Enzolytics entered into a development and manufacturing agreement with Samsung Biologics in October 2021 to act as its CDMO (Contract Development and Manufacturing Organization). Additionally, Enzolytics leveraged Intel's artificial intelligence platforms to analyze large-scale viral genomes, utilizing machine learning to map out stable, non-mutating target sites on other major pathogens, including SARS-CoV-2 and influenza.

In late 2024, Enzolytics expanded its clinical footprint by signing a three-year collaborative contract with the Department of Immunology at the Institute of Microbiology under the Bulgarian Academy of Sciences. The first project under this alliance explores the combination of Enzolytics' lyophilized pepsin with the Academy's protein-engineered cancer vaccines, specifically RtH-GD3P4 and HaH-GD3P4. In preclinical in vivo testing, these combined formulations demonstrated a remarkable capacity to suppress tumor growth, decrease tumor incidence, and prolong survival in experimental models of malignant melanoma.

To generate near-term cash flow, Enzolytics operates Virogenetics, Inc., a wholly owned subsidiary that commercializes over-the-counter nutraceutical products such as "IPF Immune," "Brain Detox," and "Liver Detox." In mid-2024, the company signed a Letter of Intent with Enogenesis (ENGN) to incorporate a patented Nitric Oxide Compound (NOC) into Virogenetics' liquid drops, pills, and sprays. While these consumer products provide a modest retail presence on platforms like Amazon and Walmart, they remain secondary to the high-stakes clinical drug development that primarily drives speculative interest in enzc stock.

Corporate Governance Crisis: The SEC Lawsuit and April 2026 Settlement

While Enzolytics' scientific portfolio has consistently generated positive headlines, its corporate governance has been plagued by severe regulatory scrutiny. The single most damaging event in the company's recent history occurred on September 30, 2024, when the Securities and Exchange Commission (SEC) filed a civil enforcement action in the U.S. District Court for the Southern District of New York (SEC v. Zhabilov et al., Case No. 1:24-cv-07362).

The SEC's complaint charged ten defendants, including former Enzolytics CEO and Chief Science Officer Harry Zhabilov, Billy Ray Jr., Charles Dilluvio, Stephen Apolant, and Harry's daughter, Dannie Zhabilov, with orchestrating a massive microcap fraud scheme. According to the regulatory filing, between 2017 and 2022, the "Control Group" accumulated billions of shares of Enzolytics stock while actively concealing their control over the company. They allegedly manufactured fraudulent consulting agreements, backdated debt contracts, and generated fake legal opinions to convert unpaid corporate debt into more than 500 million unrestricted, free-trading shares.

To bypass federal registration requirements and affiliate trading limitations, the SEC alleges that Harry Zhabilov transferred 231 million unrestricted shares to his daughter, Dannie. These shares were subsequently dumped onto unsuspecting retail investors while the Control Group funded aggressive stock promotion campaigns to artificially inflate the price of enzc stock. The scheme reportedly yielded over $92 million in illicit proceeds. The SEC highlighted that millions of dollars from these sales were routed to personal bank accounts, with Dannie Zhabilov allegedly using $7.125 million of the proceeds to purchase a luxury home, pay off her parents' primary mortgage, and lease high-end vehicles.

For over a year, this litigation hovered over Enzolytics as an existential threat, depressing the stock price and destroying investor confidence. However, a major resolution was disclosed in the company's amended annual report filed on April 18, 2026. Without admitting or denying the SEC's allegations, Harry Zhabilov entered into a formal settlement agreement. Under the terms of the settlement, Zhabilov is permanently barred for a period of five years from acting as an officer or director of any public company that utilizes OTC alternative reporting standards.

In compliance with the settlement, Harry Zhabilov immediately resigned from all officer and director positions with Enzolytics, Inc. To protect the company's ongoing research and maintain the continuity of its patented ITV-1 platform, he was transitioned to a non-executive advisory role as the company's "Chief Consulting Scientist." Following a brief and turbulent transition period involving Jeremy Frommer (CEO of Creatd, Inc., who joined the board following a strategic stock swap in early 2025 but resigned by June 2025), Diana Zhabilov was appointed as the permanent Chief Executive Officer and Chief Financial Officer. Diana, who holds a background in nursing administration and accounting, now faces the monumental task of rebuilding the company's fractured reputation and cleaning up its balance sheet.

Restructuring and the Proposed 500-to-1 Reverse Split

For long-term holders of enzc stock, the most pressing immediate concern is the company's severely damaged share structure. Due to years of aggressive debt conversions, toxic financing arrangements, and the illicit share issuances detailed in the SEC's fraud complaint, Enzolytics' capital structure has become hyper-diluted. By early 2026, the company had approximately 4.8 billion common shares outstanding.

This gargantuan share float acts as an anchor on the stock price. Even when Enzolytics publishes highly encouraging scientific updates or clinical milestones, the sheer volume of outstanding shares makes it virtually impossible for the stock to sustain upward momentum. Consequently, enzc stock has remained trapped in "triple-zero" territory, trading in a tight, illiquid range between $0.0003 and $0.0007.

To address this structural crisis, the Board of Directors voted to implement a comprehensive capital restructuring plan. On June 4, 2025, Enzolytics officially announced its intention to execute a 1-for-500 reverse stock split. The company submitted the necessary documentation to the Financial Industry Regulatory Authority (FINRA) to secure approval and obtain a new CUSIP number.

Under the terms of the proposed reverse split:

• Every 500 shares of current ENZC common stock will be consolidated into 1 post-split share.
• The total number of outstanding shares will plummet from approximately 4.8 billion to roughly 9.6 million.
• The nominal stock price will theoretically increase by a factor of 500, lifting the ticker out of sub-penny fractions and into a more respectable trading range (e.g., from $0.0005 to $0.25).

While the mathematical value of an investor's position remains identical immediately following a reverse split, the move is a double-edged sword that carries massive risks for retail shareholders. In the microcap and OTC markets, reverse splits are frequently utilized by distressed companies to artificially boost their stock price to meet the listing requirements of higher exchanges, such as the OTCQB or Nasdaq. However, without a fundamental shift in revenue generation, these splits are often followed by a renewed wave of share dilution. If Enzolytics' management resumes issuing new shares post-split to fund operations, pre-split retail investors face the very real threat of having their remaining equity diluted to near-zero.

Legal Controversies: The Nika Pharmaceuticals Patent Dispute

Adding to Enzolytics' operational headaches is an aggressive, ongoing intellectual property dispute with Nika Pharmaceuticals, Inc. (OTCQB: NIKA) and its CEO, Dimitar Savov. For several quarters, Nika has filed public documents with the SEC claiming to hold valid licensing rights to the ITV-1 compound and other core patents owned by the Zhabilov Trust.

Enzolytics' management has vigorously and repeatedly refuted these claims in public press releases and regulatory disclosures. According to Enzolytics, Nika has absolutely no legal right, title, or interest in ITV-1 or any of its derivative immunomodulatory therapies. Enzolytics' official stance asserts that:

• The patented ITV-1 technology is owned exclusively by the Zhabilov Trust.
• The trust has licensed these patents solely to Sagaliam Acquisition Corp (the entity driving Enzolytics' restructuring) through Virogenetics, Inc.
• Dimitar Savov was previously granted a consulting agreement by Enzolytics and issued 70 million shares of restricted stock.
• Savov allegedly failed to perform any of the contractually required services, and Enzolytics maintains that no valid consideration was ever provided for those shares.

This public dispute creates immense "noise" and legal uncertainty. In the biotechnology sector, a company’s valuation is almost entirely derived from the exclusivity and strength of its patents. When two public entities engage in a highly publicized war of words over the ownership of a lead drug candidate, it severely impedes the company’s ability to secure institutional partnerships, attract venture capital, or initiate large-scale clinical trials. Investors must monitor court dockets and SEC disclosures closely, as any definitive legal ruling on the ITV-1 patents will have a massive, binary impact on the value of enzc stock.

Financial Assessment: Technical Outlook and Risk Factors of ENZC Stock

From a financial planning perspective, enzc stock is an extraordinarily high-risk asset that is entirely unsuitable for traditional, conservative portfolios. The stock currently trades on the OTC Pink Limited market, which is a major warning flag for prospective buyers.

OTC Markets Group flags ENZC with a "Pink Limited Information" yield sign. This designation indicates that the company does not regularly certify its compliance with established financial reporting standards, has limited availability of public disclosure, and provides minimal financial transparency.

Furthermore, the stock is subject to SEC Rule 15c2-11 "Unsolicited Quotes Only" restrictions. This regulatory classification means that broker-dealers are prohibited from publishing competitive, proprietary bids and asks. All quotes must reflect unsolicited customer orders. For retail traders, this translates to:

• Severe Liquidity Constraints: It can be incredibly difficult to buy or sell large blocks of shares without causing massive, adverse price dislocations.
• Extremely Wide Bid-Ask Spreads: The difference between the price you can buy the stock and the price you can sell it can be as high as 50% to 100%.
• Heightened Volatility: Minimal trading volume can cause the stock price to experience wild, erratic percentage swings based on highly speculative retail sentiment.

Financially, Enzolytics operates as a pre-revenue development-stage entity. The company’s quarterly filings show negligible to zero product revenues, consistent operating losses, and a growing accumulated deficit. The company has historically survived almost entirely by converting corporate debt into equity, selling off minor assets, or entering into equity-swap arrangements.

Investor Action Guide: Buy, Hold, or Sell?

• The Bear Case (Sell / Avoid): The conservative and fundamental investment thesis dictates that investors should avoid ENZC stock entirely. The company's history is marred by a severe SEC civil fraud lawsuit, toxic dilution, an impending reverse split that could trigger further devaluation, and an ongoing patent dispute with Nika Pharmaceuticals. Without audited financials, steady revenues, or FDA-approved clinical trials, the fundamental value of the equity is functionally zero.
• The Bull Case (Speculative Hold / Lottery Play): For high-risk penny stock traders, ENZC represents a high-volatility "lotto ticket." The bull case relies entirely on a successful turnaround under CEO Diana Zhabilov. If the company can successfully execute the 500-to-1 reverse split, settle its outstanding debts, completely resolve the SEC litigation, secure its sole right to the ITV-1 patents, and successfully advance its melanoma vaccine partnership with the Bulgarian Academy of Sciences, the stock could see a massive speculative re-rating. However, any capital allocated to this stock should be treated as pure speculation—money that the investor is entirely prepared to lose.

Frequently Asked Questions (FAQ) About ENZC Stock

What is ENZC stock?

ENZC stock is the ticker symbol for Enzolytics, Inc., a microcap biotechnology company traded on the OTC Pink Limited market. The company focuses on developing peptide-based therapeutics, specifically ITV-1, and monoclonal antibodies to treat infectious diseases like HIV-1 and various cancers.

Why is ENZC stock trading at such a low price?

ENZC stock trades at sub-penny levels (under $0.001) due to extreme share dilution. Over several years, the company issued billions of shares to convert debt and fund operations, resulting in a bloated share structure of approximately 4.8 billion outstanding shares.

What was the outcome of the SEC lawsuit against Enzolytics' founder?

In April 2026, Enzolytics disclosed that founder and former CEO Harry Zhabilov settled the SEC's civil fraud lawsuit without admitting or denying the allegations. Under the settlement, Zhabilov is barred from acting as an officer or director of an OTC reporting public company for five years. He has stepped down from all executive roles and now serves as "Chief Consulting Scientist."

What is the proposed ENZC stock split?

The Board of Directors voted to implement a 1-for-500 reverse stock split. Once approved by FINRA, this restructuring will consolidate every 500 outstanding shares into 1 single share, reducing the overall share count to roughly 9.6 million and raising the nominal stock price.

Is ITV-1 FDA approved?

No, ITV-1 is not approved by the U.S. Food and Drug Administration (FDA). While it has undergone clinical and toxicology testing in Bulgaria under European Union guidelines, it remains an experimental drug candidate that requires extensive, multi-phase clinical trials before it can be commercially marketed in the United States or Europe.

Conclusion

Enzolytics, Inc. is a case study in the extreme risk and volatility of the microcap biotech sector. While its scientific concepts—such as utilizing Inactivated Pepsin Fragments (IPF) and targeting conserved viral sites with Clone 3—offer fascinating medical potential, they are heavily overshadowed by the company's severe corporate, financial, and legal challenges. The transition of Harry Zhabilov out of executive leadership following his SEC settlement, the appointment of Diana Zhabilov as CEO, and the pending 500-to-1 reverse stock split represent a desperate attempt to clean up the company's past. For retail investors looking at enzc stock, the road ahead is fraught with structural hurdles, legal battles, and liquidity risks. Diligent research, strict risk management, and a clear understanding of OTC market mechanics are absolutely vital before taking any position in this highly speculative equity.